Results 221 to 230 of about 176,389 (357)

The Bidirectional Association Between MASLD and Male Hypogonadism: An Updated Meta‐Analysis

Andrology, EarlyView.
ABSTRACT Background Metabolic dysfunction‐associated steatotic liver disease (MASLD) and male hypogonadism are increasingly prevalent, metabolically interrelated conditions. Testosterone (T) deficiency has been implicated in hepatic lipid dysregulation, insulin resistance, and visceral adiposity, whereas MASLD may impair the hypothalamic–pituitary ...
Giorgia Spaggiari, Leonardo Dalla Valentina, Cristina Felicani, Filippo Gabrielli, Simonetta Lugari, Giovanni Corona, Paolo Ventura, Manuela Simoni, Fabio Nascimbeni, Daniele Santi   +9 more
wiley   +1 more source

Predictors of High Cardiovascular Risk Among Nonobese Patients with Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease in a Chinese Population

Diabetes, Metabolic Syndrome and Obesity
Shuping Ruan,* Xiaoqing Yuan,* Juan Liu, Qing Zhang, Xinhua Ye Department of Endocrinology, The Affiliated Changzhou No. 2 People’s Hospital of Nanjing Medical University, Changzhou Medical Center, Nanjing Medical University, Changzhou, People’s ...
Ruan S, Yuan X, Liu J, Zhang Q, Ye X
doaj  

Associations of <i>Helicobacter pylori</i> infection with NAFLD, MAFLD, MASLD, and Chinese MAFLD. [PDF]

Ther Adv Gastroenterol
Yu H, Gao Y, Wang X, Chen L, Zhang Y, Li H, Méndez-Sánchez N, Qi X.   +7 more
europepmc   +1 more source

Review Article: Fibrosis Reversal in Metabolic Dysfunction‐Associated Steatohepatitis—The Promise of Emerging Therapeutics

Alimentary Pharmacology &Therapeutics, EarlyView.
Metabolic dysfunction‐associated steatohepatitis is the second commonest US indication for liver transplantation but remains largely undiagnosed and untreated. Fibrosis stage is the strongest predictor of major adverse liver outcomes, with decompensation rates and transplant‐free survival diverging sharply between F3 and F4, while cardiovascular ...
Malek Ayoub, Tsubasa Tsutsumi, Mary E. Rinella   +2 more
wiley   +1 more source

Multi-target modulation of traditional Chinese medicine based on the liver-gut axis: a new therapeutic strategy for NAFLD. [PDF]

Am J Transl Res
Lu Y, Wang L, Deng R, Sun J, Zhang H, Bao D, Zhang J.   +6 more
europepmc   +1 more source

Treatment of NAFLD with diet, physical activity and exercise.

Journal of Hepatology, 2017
M. Romero-Gómez, S. Zelber-Sagi, M. Trenell   +2 more
semanticscholar   +1 more source

Is there a role for cannabidiol in obesity, metabolic syndrome and binge eating?

British Journal of Pharmacology, EarlyView.
Cannabidiol (CBD) is one of the most abundant phytocannabinoids isolated from the Cannabis sativa plant. CBD is a lipophilic, non‐intoxicating substance that differently from Δ9‐tetrahydrocannabinol (Δ9‐THC) does not present the typical profile of a drug of abuse.
Luca Botticelli, Emanuela Micioni Di Bonaventura, Giacomo Einaudi, Gustavo Provensi, Alessia Costa, Claudio D'Addario, Carlo Cifani, Maria Vittoria Micioni Di Bonaventura   +7 more
wiley   +1 more source

Revealing the Shared Genetic Architecture of Metabolic Dysfunction-Associated Steatotic Liver Disease-Related Traits Through Genomic Structural Equation Modeling. [PDF]

Genet Epidemiol
Dong H, Li Y, Ding Q, Zhang M, Gu S, Liu M.   +5 more
europepmc   +1 more source

Re‐thinking peripheral dysfunctions in obesity: The emerging role of sulphaceutics and sulphanutraceutics

British Journal of Pharmacology, EarlyView.
Obesity is a chronic, relapsing, multisystem disease in which cardiometabolic risk arises from excess adiposity and progressive dysfunction of peripheral organs, ultimately disrupting endocrine and metabolic crosstalk among tissues. Within this network, sulphur‐based biology, centred on hydrogen sulphide and related reactive sulphur species, has ...
Martina Smimmo, Veronica Casale, Roberta d'Emmanuele di Villa Bianca, Valentina Vellecco, Mariarosaria Bucci   +4 more
wiley   +1 more source

The fibrosis-4 index for advanced liver fibrosis in NAFLD with T2DM: Half a loaf is better than no bread [PDF]

Clinical and Molecular Hepatology
Zeyu Wang, Dong Wan, Meidong Xu, Yong Jiang   +3 more
doaj   +1 more source